ストックスクリーナーアプリを入手
0.1472
4.17%
-0.0064
アフターアワーズ：
.15
0.0028
+1.90%
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech advances Ampligen for avian influenza vaccine - MSN
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist - TipRanks
AIM ImmunoTech announces a planned follow-up clinical study - GlobeNewswire
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - The Manila Times
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu - StockTitan
AIM ImmunoTech Inc (AIM) Has Recovered -14.29% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Stocks of AIM ImmunoTech Inc (AIM) are poised to climb above their peers - SETE News
Erasmus Medical Center Safety Committee Grants Approval to - GlobeNewswire
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2 - TipRanks
Investing in AIM ImmunoTech Inc (AIM) might be a great opportunity, but the stock is a bit undervalued - US Post News
Breakthrough in Pancreatic Cancer Treatment: Clinical Trial Shows 15-Month Disease Stability - StockTitan
Daily Progress: AIM ImmunoTech Inc (AIM) Drop -8.07, Closing at 0.19 - The Dwinnex
AIM’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next? - Defense World
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Marketscreener.com
AIM ImmunoTech Announces Publication of Final Clinical - GlobeNewswire
AIM ImmunoTech's Ampligen Shows Breakthrough Results in Long COVID Fatigue Treatment Trial - StockTitan
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewswire
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
AIM ImmunoTech's Ampligen Shows Breakthrough Results for Long COVID and ME/CFS Treatment - StockTitan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Allegion Plc (ALLE-N) QuotePress Release - The Globe and Mail
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewswire
AIM ImmunoTech Advances Ampligen Cancer Programs, Reports Strong Clinical Progress Across Pipeline - StockTitan
Mesoblast (NASDAQ:MESO) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast - Defense World
Analyzing Mesoblast (NASDAQ:MESO) & AIM ImmunoTech (NYSE:AIM) - Defense World
Financial Survey: AIM ImmunoTech (NYSE:AIM) and INmune Bio (NASDAQ:INMB) - Defense World
AIM ImmunoTech shareholders elect new directors amid proxy battle By Investing.com - Investing.com South Africa
AIM ImmunoTech shareholders elect new directors amid proxy battle - Investing.com
Aim Immunotech director William Mitchell sells $883 in stock - Investing.com India
Aim Immunotech director William Mitchell sells $883 in stock By Investing.com - Investing.com Australia
Declaration of Voting Results by AIM ImmunoTech - Marketscreener.com
Ted Kellner low-key on joining pharma firm board he fought to join - The Business Journals
Aim Immunotech CEO Thomas K Equels acquires $4,681 in common stock - Investing.com Canada
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - The Manila Times
AIM ImmunoTech Announces Notification of Noncompliance with - GlobeNewswire
AIM ImmunoTech Faces NYSE American Listing Crisis After 5 Years of Losses - StockTitan
Pharma company proxy fight ends in mixed results for Ted Kellner - The Business Journals
AIM ImmunoTech Strengthens Board Leadership, Advances Cancer Drug Development Strategy - StockTitan
Ted Kellner's multimillion-dollar fight to unseat pharma firm's board - The Business Journals
AIM ImmunoTech Issues an Open Letter to Shareholders - Marketscreener.com
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - GlobeNewswire Inc.
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy - Yahoo Finance
AIM ImmunoTech secures patent for post-Covid fatigue therapy - Pharmaceutical Technology
AIM ImmunoTech Inc Provides Information to the Shareholders - Marketscreener.com
1.03%
大文字化:
|
ボリューム (24 時間):